Article
How will PARP inhibitors change advanced PCa treatment?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
For more on PARP inhibitors, see: PARP inhibitor significantly extends rPFS vs. hormonal therapy
More videos:
Focal therapy vs. surveillance for low-risk PCa
Medicare final rule: Changes affect cysto, prostate Bx reimbursement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Related Content
